What is the clinical evidence from this study?

Study design: Observational. Population: Congestive heart failure (n=9). Intervention: Carvedilol vs. Baseline (before treatment). Primary outcome: Myocardial fatty acid use (μmoL · 100 g –1 · min –1) (57% decrease, p=<0.005).

What question did this study set out to answer?

This study aims to evaluate the impact of carvedilol on myocardial free fatty acid and glucose utilization in heart failure patients.

May 22, 2001Circulation

Myocardial Free Fatty Acid and Glucose Use After Carvedilol Treatment in Patients With Congestive Heart Failure

Q: What are the key findings of this study?

Carvedilol treatment in heart failure patients resulted in a 57% decrease in myocardial free fatty acid use (P<0.005) without a significant change in glucose use.

Q: What question did this study set out to answer?

This study aims to evaluate the impact of carvedilol on myocardial free fatty acid and glucose utilization in heart failure patients.

View Full Paper

Ask AI

Bookmark

Key result

Carvedilol treatment in heart failure patients resulted in a 57% decrease in myocardial free fatty acid use (P<0.005) without a significant change in glucose use.

Why the study?

Does carvedilol therapy alter myocardial free fatty acid and glucose use in patients with stable NYHA class III ischemic cardiomyopathy?

Population

9 patients with stable New York Heart Association functional class III ischemic cardiomyopathy

Comparison

Carvedilol therapy for 3 months vs Baseline (before carvedilol treatment)

Design

Cohort

Follow-up

3 months

Authors

TWThomas R. WallhausUniversity of Wisconsin System MTMichael TaylorUniversity of Notre Dame TDTimothy R. DeGradoMayo Clinic in Arizona

Discussion

Member takes

Overview

Carvedilol was associated with reduced myocardial FFA use in HF; hypothesis-generating for energy efficiency, needs prospective confirmation.

Key Points

This study aims to evaluate the impact of carvedilol on myocardial free fatty acid and glucose utilization in heart failure patients.
9 patients with ischemic cardiomyopathy (NYHA functional class III) treated with carvedilol for 3 months.
Myocardial FFA and glucose use measured using positron emission tomography with metabolic tracers [18F]-FTHA and [18F]-FDG.
Left ventricular ejection fraction assessed via echocardiograms pre- and post-treatment.
Myocardial uptake rate for [18F]-FTHA decreased from 20.4±8.6 to 9.7±2.3 mL · 100 g –1 · min –1 (P <0.005).
Fatty acid use decreased from 19.3±7.0 to 8.2±1.8 μmoL · 100 g –1 · min –1 (P <0.005).
Left ventricular ejection fraction improved from 26±2% to 37±4% (P <0.05).

Study Design

Type

Observational (n=9)

Structured PICO

Does carvedilol therapy alter myocardial free fatty acid and glucose use in patients with stable NYHA class III ischemic cardiomyopathy?

Population

9 patients with stable New York Heart Association functional class III ischemic cardiomyopathy (left ventricular ejection fraction ≤35%)

Intervention

Carvedilol therapy for 3 months

Comparator

Baseline (before carvedilol treatment)

Outcome

Myocardial free fatty acid (FFA) and glucose use measured by positron emission tomography (PET) with [18F]-FTHA and [18F]-FDGsurrogate

Main Result

Effect estimate: 57% decrease

Absolute Event Rate: 8.2% vs 19.3%

p-value: p=<0.005

Carvedilol treatment in heart failure patients significantly decreases myocardial free fatty acid use without changing glucose use, which may contribute to improved myocardial energy efficiency.

Cite This Study

Wallhaus et al. (2001) conducted an observational in Congestive heart failure (n=9). Carvedilol vs. Baseline (before treatment) was evaluated on Myocardial fatty acid use (μmoL · 100 g –1 · min –1) (57% decrease, p=<0.005). Carvedilol treatment in heart failure patients resulted in a 57% decrease in myocardial free fatty acid use (P<0.005) without a significant change in glucose use.

synapsesocial.com/papers/6a0f4100a7a2fed64abddc86 https://doi.org/10.1161/01.cir.103.20.2441

Topics

Heart failure HFrEF treatment Echocardiography HFpEF management

View Full Paper

Ask AI

Bookmark

May 22, 2001Circulation

Myocardial Free Fatty Acid and Glucose Use After Carvedilol Treatment in Patients With Congestive Heart Failure

View Full Paper

Ask AI

Bookmark

Key result

Carvedilol treatment in heart failure patients resulted in a 57% decrease in myocardial free fatty acid use (P<0.005) without a significant change in glucose use.

Why the study?

Does carvedilol therapy alter myocardial free fatty acid and glucose use in patients with stable NYHA class III ischemic cardiomyopathy?

Population

9 patients with stable New York Heart Association functional class III ischemic cardiomyopathy

Comparison

Carvedilol therapy for 3 months vs Baseline (before carvedilol treatment)

Design

Cohort

Follow-up

3 months

Authors

TWThomas R. WallhausUniversity of Wisconsin System MTMichael TaylorUniversity of Notre Dame TDTimothy R. DeGradoMayo Clinic in Arizona

Discussion

Member takes

Overview

Carvedilol was associated with reduced myocardial FFA use in HF; hypothesis-generating for energy efficiency, needs prospective confirmation.

Key Points

This study aims to evaluate the impact of carvedilol on myocardial free fatty acid and glucose utilization in heart failure patients.
9 patients with ischemic cardiomyopathy (NYHA functional class III) treated with carvedilol for 3 months.
Myocardial FFA and glucose use measured using positron emission tomography with metabolic tracers [18F]-FTHA and [18F]-FDG.
Left ventricular ejection fraction assessed via echocardiograms pre- and post-treatment.
Myocardial uptake rate for [18F]-FTHA decreased from 20.4±8.6 to 9.7±2.3 mL · 100 g –1 · min –1 (P <0.005).
Fatty acid use decreased from 19.3±7.0 to 8.2±1.8 μmoL · 100 g –1 · min –1 (P <0.005).
Left ventricular ejection fraction improved from 26±2% to 37±4% (P <0.05).

Study Design

Type

Observational (n=9)

Structured PICO

Does carvedilol therapy alter myocardial free fatty acid and glucose use in patients with stable NYHA class III ischemic cardiomyopathy?

Population

9 patients with stable New York Heart Association functional class III ischemic cardiomyopathy (left ventricular ejection fraction ≤35%)

Intervention

Carvedilol therapy for 3 months

Comparator

Baseline (before carvedilol treatment)

Outcome

Myocardial free fatty acid (FFA) and glucose use measured by positron emission tomography (PET) with [18F]-FTHA and [18F]-FDGsurrogate

Main Result

Effect estimate: 57% decrease

Absolute Event Rate: 8.2% vs 19.3%

p-value: p=<0.005

Carvedilol treatment in heart failure patients significantly decreases myocardial free fatty acid use without changing glucose use, which may contribute to improved myocardial energy efficiency.

Cite This Study

synapsesocial.com/papers/6a0f4100a7a2fed64abddc86 https://doi.org/10.1161/01.cir.103.20.2441

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Topics

Heart failure HFrEF treatment Echocardiography HFpEF management

View Full Paper

Ask AI

Bookmark